ClinicalTrials.gg
CompletedNCT04435366Updated Oct 21, 2025Results posted

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

A Phase 3 interventional study of Avacincaptad Pegol and Sham in Geographic Atrophy and Macular Degeneration, sponsored by IVERIC bio, Inc.. Completed at 205 sites in 20 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-10-21.

Sponsored by IVERIC bio, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
448
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
13th of 107
448 · median 98
Started
2020
with 9 others
Phase 3
15 of 131
2 open now
Registered
67th of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 13th largest by enrollment of the 107 interventional ones that give a count, is one of 10 that started in 2020, is one of 15 in phase 3, and was the 67th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

The objectives of this study was to evaluate the safety and efficacy of avacincaptad pegol intravitreal administration in participants with geographic atrophy secondary to age-related macular degeneration (AMD)

Read the detailed description

Participants were randomized in a 1:1 ratio to the following monthly treatment groups:

  • Avacincaptad pegol 2 mg
  • Sham

At Month 12, the participants in the avacincaptad pegol 2mg treatment group were re-randomized to receive the study drug either on a monthly basis or on an every other month basis

The participants initially randomized to sham treatment continued with monthly sham administration through Month 23

All participants had a final follow up visit at Month 24

03

Conditions studied

  • Geographic Atrophy
  • Macular Degeneration

Keywords

  • Geographic Atrophy (GA)
  • Age-related Macular Degeneration
  • AMD
  • Complement C5 inhibitor
  • avacincaptad pegol
  • IZERVAY
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects of either gender aged ≥ 50 years
  • Diagnosis of Non-foveal GA secondary to dry AMD

Exclusion criteria

Exclusion Criteria:

  • Any prior treatment for AMD (dry or wet) or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals
  • Any intraocular surgery or thermal laser within 3 months of trial entry.
  • Any prior thermal laser in the macular region, regardless of indication
  • Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks.
  • Previous therapeutic radiation in the region of the study eye
  • Any sign of diabetic retinopathy in either eye
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
448 participants (actual)

Study arms

  • Experimental
    Avacincaptad Pegol

    Participants received avacincaptad pegol (ACP) 2 milligram (mg)/eye via intravitreal (IVT) injections monthly through Month 11 (Year 1). At month 12, participants were re-randomized to receive ACP 2 mg/eye via IVT injections monthly from month12 through month 23 (Year 2).

    Drug: Avacincaptad Pegol

  • Sham comparator
    Sham

    Participants received sham injections; through Month 11 (Year 1). At month 12, participants continued to receive monthly sham administration from month 12 through month 23 (Year 2).

    Drug: Sham

  • Experimental
    Avacincaptad pegol and Sham

    Participants who received ACP 2mg monthly through Month 11 (Year 1) were re-randomized at month 12, to receive ACP 2 mg/eye via IVT injections every other month at months 13, 15, 17, 19, 21, and 23 and sham injections at months 12, 14, 16,18, 20, and 22.

    Drug: Avacincaptad Pegol

Interventions

  • Avacincaptad Pegol Intravitreal Injection

    Also known as: Zimura (previous name), IZERVAY

  • DrugSham

    Sham Administration (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection)

06

What researchers measure

Primary outcomes

  1. The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12

    GA was associated with age-related macular degeneration (AMD) and caused bilateral, progressive, and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, and choriocapillaris) leading to a permanent loss of visual function and blindness. The least squares mean used to determine mean rate of change in GA growth (slope) was measured by FAF. LS mean \& SE were based on square-root transformation.

    Time frame: Baseline to month 12

  2. The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 24

    GA was associated with AMD and caused bilateral, progressive, and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, and choriocapillaris) leading to a permanent loss of visual function and blindness. The least square mean rate of GA growth (slope) was measured by FAF. LS mean \& SE were based on untransformed data.

    Time frame: Baseline to month 24

Secondary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 24 Months

    BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS Visual Acuity Score (VAS) is defined as the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented better visual functioning. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.

    Time frame: Baseline and month 24

  2. Change From Baseline in Low Luminance (LL) BCVA Using ETDRS Letters at 24 Months

    BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS VAS is defined as the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented better visual functioning. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. LL BCVA was measured by placing a 2.0 log unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart.

    Time frame: Baseline and month 24

  3. Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 6, 12 and 18 Months

    The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. Each subscale score had a range of 0 to 100 inclusive and were calculated from the re-scaled raw data. A composite score was derived based on the average of the 11 vision-related subscales.

    Time frame: Baseline, months 6, 12, and 18

  4. Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 24 Months

    The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. Each subscale score had a range of 0 to 100 inclusive and were calculated from the re-scaled raw data. A composite score was derived based on the average of the 11 vision-related subscales.

    Time frame: Baseline and month 24

  5. Number of Participants With Categorical One-level Loss in VFQ-25 Subscale

    The National Eye Institute VFQ-25 measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively.Categorical one-level loss in each item was defined as decline of one or more levels at Month 24 on the original scale from Baseline (equivalently 20 points for general vision and 25 points for other vision items in a 0 to 100 scale).

    Time frame: Baseline up to month 24

  6. Time to Persistent Vision Loss

    Vision loss event was defined as a loss of ≥ 15 letters (equivalent to a loss of 3 lines on the ETDRS chart) in BCVA from Baseline measured at any two or more consecutive visits up to Month 24. These parameters were chosen as a 3-line BCVA loss (equivalent to doubling of visual angle) is widely recognized as a significant deterioration in vision and a minimum of two consecutive visits was representative of persistent disease progression. BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS VAS was defined as the number of letters read on the ETDRS chart. Min and max possible scores are 0-100. A higher score represents better visual functioning. Kaplan-Meier method was used for analysis. Participants with an event were reported and not the median time to event.

    Time frame: Baseline up to month 24

07

Results

Posted Dec 28, 2023

Participant flow

Participants ≥ 50 years of age diagnosed with geographic atrophy (GA) that was at least partly within 1.5 mm radius from the foveal center were enrolled in the study.

Year 1 (12 Months)
Participant flow — Year 1 (12 Months)
MilestoneAvacincaptad PegolAvacincaptad Pegol and ShamSham
Started2250223
Treated2250222
Completed2000205
Not completed25018
Withdrew: Adverse event302
Withdrew: Death201
Withdrew: Lost to follow-up201
Withdrew: Withdrawal by subject17013
Withdrew: Patient non-compliance100
Withdrew: Not treated001
Year 2 (12 Months)
Participant flow — Year 2 (12 Months)
MilestoneAvacincaptad PegolAvacincaptad Pegol and ShamSham
Started9693203
Completed8983184
Not completed71019
Withdrew: Death146
Withdrew: Lost to follow-up020
Withdrew: Withdrawal by subject437
Withdrew: Adverse event216

Outcome measures

PrimaryThe Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12

GA was associated with age-related macular degeneration (AMD) and caused bilateral, progressive, and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, and choriocapillaris) leading to a permanent loss of visual function and blindness. The least squares mean used to determine mean rate of change in GA growth (slope) was measured by FAF. LS mean \& SE were based on square-root transformation.

Time frame:
Baseline to month 12
Reported as:
Least squares mean · millimeters (mm)/year
The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12
millimeters (mm)/yearAvacincaptad PegolSham
The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 120.336 ± 0.0320.392 ± 0.033
Statistical analysis
  • Avacincaptad Pegol vs Sham · MMRM · p = 0.0064 (Nominal p-value was used for the comparison between avacincaptad pegol versus sham.) · Least squares mean difference: 0.056 · 95% CI 0.016 to 0.096
PrimaryThe Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 24

GA was associated with AMD and caused bilateral, progressive, and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, and choriocapillaris) leading to a permanent loss of visual function and blindness. The least square mean rate of GA growth (slope) was measured by FAF. LS mean \& SE were based on untransformed data.

Time frame:
Baseline to month 24
Reported as:
Least squares mean · mm^2/year
The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 24
mm^2/yearAvacincaptad PegolAvacincaptad Pegol and ShamSham
The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 242.23 ± 0.1242.10 ± 0.1262.59 ± 0.085
Statistical analysis
  • Avacincaptad Pegol vs Sham · MMRM · p = 0.0165 (Nominal p-value was used for the comparison between avacincaptad pegol versus sham.) · Least squares mean difference: 0.362 · 95% CI 0.066 to 0.657
  • Avacincaptad Pegol and Sham vs Sham · MMRM · p = 0.0015 (Nominal p-value was used for the comparison between avacincaptad pegol and sham versus sham.) · Least squares mean difference: 0.488 · 95% CI 0.189 to 0.788
SecondaryChange From Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 24 Months

BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS Visual Acuity Score (VAS) is defined as the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented better visual functioning. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.

Time frame:
Baseline and month 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 24 Months
score on a scaleAvacincaptad PegolSham
Change From Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 24 Months-7.31 ± 1.07-6.48 ± 1.05
Statistical analysis
  • Avacincaptad Pegol vs Sham · MMRM · p = 0.58 (Nominal p-value was used for the comparison between avacincaptad pegol versus sham.) · Least squares mean difference: -0.83 · 95% CI -3.79 to 2.12
SecondaryChange From Baseline in Low Luminance (LL) BCVA Using ETDRS Letters at 24 Months

BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS VAS is defined as the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented better visual functioning. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. LL BCVA was measured by placing a 2.0 log unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart.

Time frame:
Baseline and month 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Low Luminance (LL) BCVA Using ETDRS Letters at 24 Months
score on a scaleAvacincaptad PegolSham
Change From Baseline in Low Luminance (LL) BCVA Using ETDRS Letters at 24 Months-10.58 ± 1.20-9.1 ± 1.18
Statistical analysis
  • Avacincaptad Pegol vs Sham · MMRM · p = 0.38 (Nominal p-value was used for the comparison between avacincaptad pegol versus sham.) · Least squares mean difference: -1.49 · 95% CI -4.79 to 1.81
SecondaryChange From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 6, 12 and 18 Months

The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. Each subscale score had a range of 0 to 100 inclusive and were calculated from the re-scaled raw data. A composite score was derived based on the average of the 11 vision-related subscales.

Time frame:
Baseline, months 6, 12, and 18
Reported as:
Mean · score on a scale
Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 6, 12 and 18 Months
score on a scaleAvacincaptad PegolSham
Change at 6 months-1.2 ± 10.56-1.6 ± 9.98
Change at 12 months-3.4 ± 11.05-3.6 ± 11.01
Change at 18 months-5.4 ± 12.80-4.7 ± 11.53
SecondaryChange From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 24 Months

The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. Each subscale score had a range of 0 to 100 inclusive and were calculated from the re-scaled raw data. A composite score was derived based on the average of the 11 vision-related subscales.

Time frame:
Baseline and month 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 24 Months
score on a scaleAvacincaptad PegolSham
Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 24 Months-7.735 ± 0.950-7.023 ± 0.931
Statistical analysis
  • Avacincaptad Pegol vs Sham · MMRM · p = 0.5929 · Least square mean difference: -0.712 · 95% CI -3.326 to 1.903
SecondaryNumber of Participants With Categorical One-level Loss in VFQ-25 Subscale

The National Eye Institute VFQ-25 measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively.Categorical one-level loss in each item was defined as decline of one or more levels at Month 24 on the original scale from Baseline (equivalently 20 points for general vision and 25 points for other vision items in a 0 to 100 scale).

Time frame:
Baseline up to month 24
Reported as:
Number · participants
Number of Participants With Categorical One-level Loss in VFQ-25 Subscale
participantsAvacincaptad PegolSham
Color Vision4535
Distance Vision5643
Near Vision6149
Peripheral Vision5865
General Vision5858
Dependency5555
Driving2726
General Health4567
Mental Health3542
Ocular Pain2720
Role Difficulties6059
Social Function5252
SecondaryTime to Persistent Vision Loss

Vision loss event was defined as a loss of ≥ 15 letters (equivalent to a loss of 3 lines on the ETDRS chart) in BCVA from Baseline measured at any two or more consecutive visits up to Month 24. These parameters were chosen as a 3-line BCVA loss (equivalent to doubling of visual angle) is widely recognized as a significant deterioration in vision and a minimum of two consecutive visits was representative of persistent disease progression. BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS VAS was defined as the number of letters read on the ETDRS chart. Min and max possible scores are 0-100. A higher score represents better visual functioning. Kaplan-Meier method was used for analysis. Participants with an event were reported and not the median time to event.

Time frame:
Baseline up to month 24
Reported as:
Median · months
Time to Persistent Vision Loss
monthsAvacincaptad PegolSham
Time to Persistent Vision Loss17.02 (2.8 to 23.0)13.93 (1.3 to 23.2)
Statistical analysis
  • Avacincaptad Pegol vs Sham · Log Rank · p = 0.6424 · Hazard ratio (hr): 0.90 · 95% CI 0.57 to 1.42

Adverse events

Collected over All-cause mortality (ACM): From randomization up to 24 months Serious Adverse events (SAEs) and non-SAEs: From first dose up to 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Avacincaptad Pegol Only (up to 12 Months)4/225 (1.8%)31/225 (13.8%)100/225 (44.4%)
Avacincaptad Pegol Only (12 to 24 Months)1/96 (1%)18/96 (18.8%)51/96 (53.1%)
Avacincaptad Pegol and Sham Only (12 to 24 Months)4/93 (4.3%)16/93 (17.2%)41/93 (44.1%)
Sham Only (up to 12 Months)1/222 (0.5%)36/222 (16.2%)83/222 (37.4%)
Sham Only (12 to 24 Months)7/203 (3.4%)25/203 (12.3%)77/203 (37.9%)
Most frequent serious events
Showing 10 of 117
Most frequent serious events
EventAvacincaptad Pegol Only (up to 12 Months)Avacincaptad Pegol Only (12 to 24 Months)Avacincaptad Pegol and Sham Only (12 to 24 Months)Sham Only (up to 12 Months)Sham Only (12 to 24 Months)
Chest painGeneral disorders0/2250/962/930/2220/203
Cerebrovascular accidentNervous system disorders1/2250/961/931/2223/203
Microcytic anaemiaBlood and lymphatic system disorders0/2250/961/930/2220/203
Normocytic anaemiaBlood and lymphatic system disorders0/2250/961/930/2220/203
Atrial tachycardiaCardiac disorders0/2250/961/930/2220/203
Cardiac failure congestiveCardiac disorders1/2250/961/931/2220/203
Barrett's oesophagusGastrointestinal disorders0/2250/961/930/2220/203
Gastric haemorrhageGastrointestinal disorders0/2250/961/930/2220/203
Biliary obstructionHepatobiliary disorders0/2250/961/930/2220/203
Clostridium difficile infectionInfections and infestations1/2250/961/930/2220/203
Most frequent other events
Showing 10 of 11
Most frequent other events
EventAvacincaptad Pegol Only (up to 12 Months)Avacincaptad Pegol Only (12 to 24 Months)Avacincaptad Pegol and Sham Only (12 to 24 Months)Sham Only (up to 12 Months)Sham Only (12 to 24 Months)
COVID-19Infections and infestations7/22511/9614/937/22226/203
Conjunctival haemorrhageEye disorders31/22514/969/9318/2225/203
Choroidal neovascularisationEye disorders21/22511/968/9311/22219/203
Intraocular pressure increasedInvestigations22/2259/965/934/2221/203
FallInjury, poisoning and procedural complications14/2259/968/9317/22212/203
Urinary tract infectionInfections and infestations14/2253/962/9313/22218/203
CataractEye disorders6/2257/964/939/22210/203
Punctate keratitisEye disorders14/2255/965/9315/2225/203
NasopharyngitisInfections and infestations4/2254/966/936/2223/203
Conjunctival hyperaemiaEye disorders12/2251/961/9313/2225/203

Baseline characteristics

Intent-to-treat (ITT) analysis set consisted of all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)Avacincaptad PegolShamTotal
Mean76.3 ± 8.676.7 ± 8.876.5 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Avacincaptad PegolShamTotal
Female154156310
Male7166137
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Avacincaptad PegolShamTotal
Hispanic or Latino272350
Not Hispanic or Latino168178346
Unknown or Not Reported302151
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Avacincaptad PegolShamTotal
American Indian or Alaska Native101
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American011
White182186368
More than one race000
Unknown or Not Reported413475
08

Study locations

205 sites
  • Retina-Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • Retinal Diagnostic Center
    Campbell, California 95008, United States
  • Eye Medical Center of Fresno
    Fresno, California 93720, United States
  • Retina Consultants of Orange County
    Fullerton, California 92835, United States
  • University of California, San Diego
    La Jolla, California 92093, United States
  • Jules Stein Eye Institute/David Geffen School of Medicine
    Los Angeles, California 90095, United States
  • Northern California Retina Vitreous Associates
    Mountain View, California 94040, United States
  • California Retina Consultants
    Oxnard, California 93036, United States
  • Southern California Desert Retina Consultants
    Palm Desert, California 92211, United States
  • Doheny Eye Center, UCLA
    Pasadena, California 91105, United States
  • Retina Consultants of Southern California
    Redlands, California 92374, United States
  • Retinal Consultants Medical Group, Inc.
    Sacramento, California 95825, United States
  • Orange County Retinal Medical Group
    Santa Ana, California 92705, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Retina Consultants of Southern Colorado, P.C.
    Colorado Springs, Colorado 80909, United States
  • Colorado Retina Associates
    Lakewood, Colorado 80228, United States
  • Connecticut Eye Consultants, P.C.
    Danbury, Connecticut 06810, United States
  • Retina Group of New England, PC
    Waterford, Connecticut 06385, United States
  • Florida Eye Clinic
    Altamonte Springs, Florida 32701, United States
  • Rand Eye Institute
    Deerfield Beach, Florida 33064, United States
  • Retina Group of Florida
    Fort Lauderdale, Florida 33308, United States
  • Retina Health Center
    Fort Myers, Florida 33907, United States
  • National Ophthalmic Research Institute
    Fort Myers, Florida 33912, United States
  • VitreoRetinal Associates, P.A.
    Gainesville, Florida 32607, United States
  • Florida Eye Associates
    Melbourne, Florida 32901, United States
  • University of Miami-Bascom Palmer Eye Institute
    Miami, Florida 33136, United States
  • Retina Care Specialists
    Palm Beach Gardens, Florida 33410, United States
  • Retina Specialty Institute
    Pensacola, Florida 32503, United States
  • Retina Associates of Sarasota
    Sarasota, Florida 34233, United States
  • Retina Vitreous Associates of Florida
    St. Petersburg, Florida 33711, United States
  • East Florida Eye Institute
    Stuart, Florida 34994, United States
  • Southern Vitreoretinal Associates, PL
    Tallahassee, Florida 32308, United States
  • Center for Retina and Macula Disease
    Winter Haven, Florida 33880, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Georgia Retina, P.C.
    Marietta, Georgia 30060, United States
  • Retina Consultants of Hawaii, Inc
    ‘Aiea, Hawaii 96701, United States
  • University Retina and Macula Associates, PC
    Lemont, Illinois 60439, United States
  • Illinois Eye Center
    Peoria, Illinois 61615, United States
  • Midwest Eye Institute
    Indianapolis, Indiana 46290, United States
  • Wolfe Eye Clinic
    West Des Moines, Iowa 50266, United States
  • Retina Associates, LLC
    Lenexa, Kansas 66215, United States
  • Vitreo Retinal Consultants & Surgeons
    Wichita, Kansas 67214, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
  • The Retina Care Center
    Baltimore, Maryland 21209, United States
  • The Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • Retina Research Institute at New England Retinal Consultants
    Springfield, Massachusetts 01107, United States
  • UMASS Memorial Eye Center
    Worcester, Massachusetts 01605, United States
  • Vitreoretinal Associates, PC
    Worcester, Massachusetts 01605, United States
  • Associated Retinal Consultants, P.C.
    Royal Oak, Michigan 48073, United States
  • Retina Center
    Minneapolis, Minnesota 55404, United States
  • St. Louis University
    St Louis, Missouri 63110, United States
  • Retina Consultants of Nevada
    Henderson, Nevada 89052, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • Retina Center of New Jersey, LLC
    Bloomfield, New Jersey 07003, United States
  • Long Island Vitreoretinal Consultant
    Great Neck, New York 11021, United States
  • Retina Vitreous Surgeons of Central New York, PC
    Liverpool, New York 13088, United States
  • Vitreous Retina Macula Consultants of New York (VRMNY)
    New York, New York 10022, United States
  • OCLI
    Oceanside, New York 11572, United States
  • Retina Associates of Western NY, PC
    Rochester, New York 14620, United States
  • Ophthalmic Consultants of the Capital Region
    Troy, New York 12180, United States
  • Western Carolina Retinal Associates
    Asheville, North Carolina 28803, United States
  • Cincinnati Eye Institute
    Cincinnati, Ohio 45242, United States
  • Retina and Vitreous Center of Southern Oregon
    Ashland, Oregon 97520, United States
  • Retina Northwest, PC
    Portland, Oregon 97221, United States
  • EyeHealth Northwest
    Portland, Oregon 97225, United States
  • Casey Eye Institute
    Portland, Oregon 97239, United States
  • Scheie Eye Institute, University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Mid Atlantic Retina
    Philadelphia, Pennsylvania 19107, United States
  • Associates in Ophthalmology, Ltd
    West Mifflin, Pennsylvania 15122, United States
  • Retina Research of Beaufort, LLC
    Beaufort, South Carolina 29902, United States
  • Charleston Neuroscience Institute
    Ladson, South Carolina 29456, United States
  • Carolina Macula and Retina
    Mt. Pleasant, South Carolina 29464, United States
  • Palmetto Retina Center
    West Columbia, South Carolina 29169, United States
  • Black Hills Regional Eye Institute
    Rapid City, South Dakota 57701, United States
  • Southeastern Retina Associates, PC
    Johnson City, Tennessee 37604, United States
  • Southeastern Retina Associates, PC
    Knoxville, Tennessee 37922, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Southwest Retina Specialists
    Amarillo, Texas 79106, United States
  • Austin Retina Associates
    Austin, Texas 78705, United States
  • Retina Foundation of the Southwest
    Dallas, Texas 75231, United States
  • Retina and Vitreous of Texas, PLLC
    Houston, Texas 77025, United States
  • Valley Retina Institute
    McAllen, Texas 78503, United States
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240, United States
  • Retina Center of Texas
    Southlake, Texas 76092, United States
  • Retinal Consultants of Houston
    The Woodlands, Texas 77384, United States
  • Strategic Clinical Research Group
    Willow Park, Texas 76087, United States
  • Retinal Associates of Utah
    Salt Lake City, Utah 84107, United States
  • Rocky Mountain Retina Consultants
    Salt Lake City, Utah 84107, United States
  • University of Utah, John A. Moran Eye Center
    Salt Lake City, Utah 84132, United States
  • Wagner Macular & Retina Center
    Norfolk, Virginia 23502, United States
  • Retina Institute of Virginia
    Richmond, Virginia 23235, United States
  • Vistar Eye Center
    Roanoke, Virginia 24018, United States
  • Pacific Northwest Retina
    Bellevue, Washington 98004, United States
  • Retina Center NW, PLLC
    Silverdale, Washington 98383, United States
  • Centro Oftalmológico Dr. Charles SA
    Buenos Aires, Buenos Aires F.D. C1116ABA, Argentina
  • Buenos Aires Macula S.A.
    Buenos Aires, Buenos Aires F.D. Cl061AAE, Argentina
  • Centro Médico Grupo Laser Visión
    Rosario, Santa Fe Province CP2000, Argentina
  • Centro de Diagnóstico y Cirugía Ocular "Oftalmólogos Especialistas"
    Rosario, Santa Fe Province S2000ANJ, Argentina

Showing the first 100 of 205 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Khanani AM, Danzig CJ, Heier JS, Jaffe GJ, Kaiser PK, Lally DR, Patel SS, Vajzovic L, Weng CY, Patel H, Clark J, Desai D, Luo D, Henry E, Holz FG; GATHER2 Trial Investigators. Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial. Ophthalmology. 2026 Apr;133(4):451-465. doi: 10.1016/j.ophtha.2025.12.011. Epub 2025 Dec 15. PubMed 41407269 ↗
  • Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Mones J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. PubMed 37696275 ↗
  • Tzoumas N, Riding G, Williams MA, Steel DH. Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD009300. doi: 10.1002/14651858.CD009300.pub3. PubMed 37314061 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Jul 2022, 25 months.

Results were first posted in Dec 2023, 1 year 5 months after primary completion. A results delay was requested in Jul 2023.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2020
First posted
Jun 17, 2020
StartActual
Jun 22, 2020
Primary completionActual
Jul 25, 2022
CompletionActual
Aug 22, 2023
Results delay requested
Jul 21, 2023
Results first posted
Dec 28, 2023
Last update
Oct 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04435366
Lead sponsor
IVERIC bio, Inc.
Responsible party
Sponsor
First posted
Jun 17, 2020
Start date
Jun 22, 2020
Primary completion
Jul 25, 2022
Completion
Aug 22, 2023
Results posted
Dec 28, 2023
Last update
Oct 21, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avacincaptad pegol

Start the discussion